The reno-protective effects of atorvastatin in crush syndrome and rhabdomyolysis: is there a dilemma?

Basit Öğe Kaydı
dc.contributor.authorAcar, Demet
dc.contributor.authorGulpembe, Mustafa
dc.contributor.authorYildiz, Can Gokay
dc.contributor.authorOzdamar, Emine Nur
dc.contributor.authorAcikgoz, Kerem
dc.contributor.authorCaglar, Ahmet
dc.contributor.authorCander, Basar
dc.date.accessioned2024-02-23T14:37:22Z
dc.date.available2024-02-23T14:37:22Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractBackground/aim: We aim to determine the effects of low-dose atorvastatin treatment together with crush fluid resuscitation on renal functions and muscle enzyme levels in a rat model of crush syndrome. Materials and methods: The study involved female Wistar Albino rats weighing 250-300 g that were housed with free access to food and water. The crush model was obtained by compression. Rats were randomly divided into four groups: control (C) group, atorvastatin + crush fluid (ACF) group, crush fluid (CF) group, and hypertonic saline (% 3) + mannitol + sodium bicarbonate (SM) group. Blood was obtained at 24, 48, and 72 h, and serum creatinine kinase, myoglobin, urea, creatinine, and lactate dehydrogenase levels were studied. Results: All parameters were statistically significantly higher in the control group than in the treatment groups at all hours. However, there was no statistically significant difference among treatment groups regarding any of the parameters. Conclusion: This is the first study determining the role of atorvastatin in the treatment of renal ischemia/reperfusion injury in a crush syndrome and rhabdomyolysis model setting. Larger studies with different atorvastatin doses are required to define the role of this drug in the treatment of renal ischemia/reperfusion injury during crush syndrome.en_US
dc.identifier.doi10.3906/sag-1610-48
dc.identifier.endpage1924en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue6en_US
dc.identifier.pmid29306258en_US
dc.identifier.scopus2-s2.0-85038421805en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1920en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1610-48
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16074
dc.identifier.volume47en_US
dc.identifier.wosWOS:000418884300037en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCrush Syndromeen_US
dc.subjectAtorvastatinen_US
dc.subjectRhabdomyolysisen_US
dc.titleThe reno-protective effects of atorvastatin in crush syndrome and rhabdomyolysis: is there a dilemma?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu